111 related articles for article (PubMed ID: 36931572)
1. Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial of
Allen SG; Rosen BS; Aryal M; Cao Y; Schipper MJ; Wong KK; Casper KA; Chinn SB; Malloy KM; Prince ME; Rosko AJ; Shuman AG; Spector ME; Stucken CL; Swiecicki PL; Worden FP; Brenner JC; Schonewolf CA; Elliott DA; Mierzwa ML; Shah JL
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):171-180. PubMed ID: 36931572
[TBL] [Abstract][Full Text] [Related]
2. CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
Rosen BS; Wilkie JR; Sun Y; Ibrahim M; Casper KA; Miller JE; Chotchutipan T; Stucken CL; Bradford C; Prince MEP; Rosko AJ; Malloy KM; McLean SA; Chinn SB; Shuman AG; Spector ME; Swiecicki PL; Worden FP; Shah JL; Schonewolf CA; Chapman CH; Eisbruch A; Mierzwa ML
Radiother Oncol; 2021 Feb; 155():174-181. PubMed ID: 33069764
[TBL] [Abstract][Full Text] [Related]
3. Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning.
Chen TM; Chen WM; Chen M; Shia BC; Wu SY
J Otolaryngol Head Neck Surg; 2023 Feb; 52(1):14. PubMed ID: 36782296
[TBL] [Abstract][Full Text] [Related]
4. Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the Oropharynx.
Waddle MR; Ma DJ; Visscher SL; Borah BJ; May JM; Price KA; Moore EJ; Patel SH; Hinni ML; Chintakuntlawar AV; Garcia JJ; Graner DE; Neben-Wittich MA; Garces YI; Hallemeier CL; Price DL; Kasperbauer JL; Janus JR; Foote RL; Miller RC
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):396-402. PubMed ID: 33359567
[TBL] [Abstract][Full Text] [Related]
5. Single-Center Prospective Trial Investigating the Feasibility of Serial FDG-PET Guided Adaptive Radiation Therapy for Head and Neck Cancer.
Gouw ZAR; La Fontaine MD; Vogel WV; van de Kamer JB; Sonke JJ; Al-Mamgani A
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):960-968. PubMed ID: 32361007
[TBL] [Abstract][Full Text] [Related]
6. Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma.
Lee N; Schoder H; Beattie B; Lanning R; Riaz N; McBride S; Katabi N; Li D; Yarusi B; Chan S; Mitrani L; Zhang Z; Pfister DG; Sherman E; Baxi S; Boyle J; Morris LG; Ganly I; Wong R; Humm J
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):9-17. PubMed ID: 27511842
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity and irregularity of pretreatment
Cheng NM; Fang YD; Tsan DL; Lee LY; Chang JT; Wang HM; Ng SH; Liao CT; Yang LY; Yen TC
Oral Oncol; 2018 Mar; 78():156-162. PubMed ID: 29496044
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status.
Kikuchi M; Koyasu S; Shinohara S; Usami Y; Imai Y; Hino M; Itoh K; Tona R; Kanazawa Y; Kishimoto I; Harada H; Naito Y
Head Neck; 2015 Oct; 37(10):1524-31. PubMed ID: 24890445
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer.
Rasmussen JH; Håkansson K; Vogelius IR; Aznar MC; Fischer BM; Friborg J; Loft A; Kristensen CA; Bentzen SM; Specht L
Radiother Oncol; 2016 Jul; 120(1):76-80. PubMed ID: 26993418
[TBL] [Abstract][Full Text] [Related]
10.
Subramaniam RM; DeMora L; Yao M; Yom SS; Gillison M; Caudell JJ; Waldron J; Xia P; Chung CH; Truong MT; Echevarria M; Chan JW; Geiger JL; Mell L; Seaward S; Thorstad WL; Beitler JJ; Sultanem K; Blakaj D; Le QT
J Nucl Med; 2023 Mar; 64(3):362-367. PubMed ID: 36215572
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of (18)F-FDG PET combined with expression of EGFR may improve the prognostic stratification of advanced oropharyngeal carcinoma.
Wang HM; Cheng NM; Lee LY; Fang YH; Chang JT; Tsan DL; Ng SH; Liao CT; Yang LY; Yen TC
Int J Cancer; 2016 Feb; 138(3):731-8. PubMed ID: 26311121
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of
Berwouts D; Madani I; Duprez F; Olteanu AL; Vercauteren T; Boterberg T; Deron P; Bonte K; Huvenne W; De Neve W; Goethals I
Head Neck; 2017 Nov; 39(11):2264-2275. PubMed ID: 28833829
[TBL] [Abstract][Full Text] [Related]
13. Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.
Ma DJ; Price KA; Moore EJ; Patel SH; Hinni ML; Garcia JJ; Graner DE; Foster NR; Ginos B; Neben-Wittich M; Garces YI; Chintakuntlawar AV; Price DL; Olsen KD; Van Abel KM; Kasperbauer JL; Janus JR; Waddle M; Miller R; Shiraishi S; Foote RL
J Clin Oncol; 2019 Aug; 37(22):1909-1918. PubMed ID: 31163012
[TBL] [Abstract][Full Text] [Related]
14. Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer.
Chen SW; Hsieh TC; Yen KY; Yang SN; Wang YC; Chien CR; Liang JA; Kao CH
Laryngoscope; 2014 Dec; 124(12):2732-8. PubMed ID: 25042474
[TBL] [Abstract][Full Text] [Related]
15. Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence.
Sivarajah S; Isaac A; Cooper T; Zhang H; Puttagunta L; Abele J; Biron V; Harris J; Seikaly H; O' Connell DA
JAMA Otolaryngol Head Neck Surg; 2018 Nov; 144(11):1037-1043. PubMed ID: 30242338
[TBL] [Abstract][Full Text] [Related]
16. Use of Diffusion-Weighted Imaging and
Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
[TBL] [Abstract][Full Text] [Related]
17. Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease.
Pellini R; Manciocco V; Turri-Zanoni M; Vidiri A; Sanguineti G; Marucci L; Sciuto R; Covello R; Sperduti I; Kayal R; Anelli V; Pichi B; Mercante G; Spriano G
J Craniomaxillofac Surg; 2014 Dec; 42(8):1834-9. PubMed ID: 25150165
[TBL] [Abstract][Full Text] [Related]
18. The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection.
Tapia M; Manji J; Dhillon K; Kleid S; Flatman S; Prasad J; Cardin A; Fua T; Rischin D; Dixon B; J R Magarey M
Oral Oncol; 2022 Dec; 135():106213. PubMed ID: 36274346
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of matted lymphadenopathy in patients with oropharyngeal squamous cell carcinoma treated with definitive chemoradiotherapy.
Burningham K; Moore W; Moon D; Avkshtol V; Day AT; Sumer B; Vo D; Bishop JA; Hughes R; Sher DJ
Oral Oncol; 2021 Dec; 123():105623. PubMed ID: 34801975
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of FDG-PET volumetric parameters in patients with p16-positive oropharyngeal squamous cell carcinoma who received curative resection followed by postoperative radiotherapy or chemoradiotherapy.
Kim KH; Lee J; Chang JS; Lee CG; Yun M; Choi EC; Kim SH; Keum KC
Head Neck; 2016 Oct; 38(10):1515-24. PubMed ID: 27062085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
